TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01132482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo will have sham dose escalation to maintain blinding.
Study: NCT02901535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Spirometry in baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry in baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: telemonitoring (phone call nurse - 45 and 90 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teleconsultation
Description: teleconsultation (general practioner received phone call to respiratory care)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry - 20 weeks
Description: Spirometry (20 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry - 20 weeks
Description: Spirometry (20 weeks)
Study: NCT02093338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: maltodextrin
Description: Placebo
Study: NCT01195493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oils solution
Description: (Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: negative control solution
Description: this solution would be used twice per day (2 x 20 ml) following daily home care.
Study: NCT02821364

Intervention type: OTHER
Group type: OTHER
Intervention: Advanced Life Support
Description: IV FLUIDS, INTUBATION
Study: NCT00810784

Intervention type: BEHAVIORAL
Intervention: Education
Description: (1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
Study: NCT02816619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity coaching program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Free practice of physical activity
Study: NCT02641717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal swab
Study: NCT00294255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
Study: NCT03222414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BP recording with conical Ultracheck Curve BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive BP recording with conical Ultracheck Curve BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BP recording with traditional cylindrical BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive BP recording with traditional cylindrical BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct invasive arterial pressure
Description: Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct invasive arterial pressure
Description: Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
Study: NCT02460341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 8mg, 16mg, 24mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 8mg, 16mg, 24mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 8mg, 16mg, 24mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo pill
Study: NCT02924311

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
Study: NCT06113276

Intervention type: RADIATION
Intervention: Low dose computed tomography to evaluate biomechanical parameters in the lung
Description: In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
Study: NCT01501552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-SBI (online screening and brief intervention)
Description: Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-SBI (online screening and brief intervention)
Description: Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-SBI (online screening and brief intervention)
Description: Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
Study: NCT02399202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Study: NCT02291549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study: NCT01501552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-SBI (online screening and brief intervention)
Description: Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
Study: NCT03222947

Intervention type: GENETIC
Intervention: Deoxyribonucleic acid analysis
Description: This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).

Intervention type: GENETIC
Intervention: Deoxyribonucleic acid analysis
Description: This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
Study: NCT00580762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-y gastric bypass (RYGB)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-y gastric bypass (RYGB)
Study: NCT04405245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost opthalmic solution to be dosed once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost opthalmic solution to be dosed once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost opthalmic solution to be dosed once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 4%
Description: Razuprotafib opthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 4%
Description: Razuprotafib opthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for razuprotafib opthalmic solution
Study: NCT05993962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified yoghurt
Description: Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control yoghurt
Description: Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
Study: NCT02986113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAPS tailored multimedia patient activation program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene video
Description: 3 minute video on sleep hygiene produced by HealthiNation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone evidence-based follow-up care
Description: 3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone evidence-based follow-up care
Description: 3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment to Living for Primary Care
Description: Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commitment to Living for Primary Care
Description: Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
Study: NCT04491851

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT
Description: Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
Study: NCT01632527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
Study: NCT04491851

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT
Description: Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
Study: NCT03836677

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BGF
Description: Treatment with Budesonide/Glycopyrronium/FormoterolFumarate

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BGF
Description: Treatment with Budesonide/Glycopyrronium/FormoterolFumarate

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GFF
Description: Treatment with Glycopyrronium/Formoterol Fumarate

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GFF
Description: Treatment with Glycopyrronium/Formoterol Fumarate
Study: NCT02350504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full interactive instruction
Description: This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
Study: NCT06421922

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 received a regular constipation diet
Description: Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 received a constipation diet rich in soluble fiber
Description: Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 received a constipation diet supplemented with probiotic yogurt.
Description: Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks.
Study: NCT03370562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administration of 10 mcg intravenous dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of normal saline
Study: NCT02195167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Description: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there
Study: NCT03292276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo Training
Description: To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amadeo Training
Description: To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups.
Study: NCT00673283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bi-plane chest radiography
Description: Bi-plane radiography of the thorax
Study: NCT01786252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG)
Description: 500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator (for hCG)
Description: 50ul of IVF medium (Global-trademark) to mimic hCG infusion
Study: NCT02809963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 50 mg tablets, oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg tablets, oral use
Study: NCT01480401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-sodium diet (1500 mg daily)
Study: NCT03688100

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation Therapy
Description: The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management
Description: Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
Study: NCT04079881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
Study: NCT03907462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART 2.0
Description: SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART 2.0
Description: SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
Study: NCT04005079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Standard of Care
Study: NCT01184417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg/kg IV phenobarbital in 100 ml saline
Description: 10 mg/kg IV phenobarbital in 100 ml saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 m l saline
Study: NCT01262664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prohibitin-TP01
Description: Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
Study: NCT00147004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone sodium succinate
Description: 50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00307866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resovist (BAY86-4884, SH U 555 A)
Description: Single bolus injection, followed by MRI